Leucovorin a nd F luorouracil W ith o r W ithout O xaliplatin as F irst-Line T reatment i n A dvanced C olorectal C ancer

Purpose: In a previous study of treatment for advanced colorectal cancer, the LV5FU2 regimen, comprising leucovorin (LV) plus bolus and infusional fluorouracil (5FU) every 2 weeks, was superior to the standard North Central Cancer Treatment Group/Mayo Clinic 5-day bolus 5FU/LV regimen. This phase III study investigated the effect of combining oxaliplatin with LV5FU2, with progression-free survival as the primary end point. Patients and Methods: Four hundred twenty previously untreated patients with measurable disease were randomized to receive a 2-hour infusion of LV (200 mg/m 2 /d) followed by a 5FU bolus (400 mg/m 2 /d) and 22-hour infusion (600 mg/m 2 /d) for 2 consecutive days every 2 weeks, either alone or together with oxaliplatin 85 mg/m 2 as a 2-hour infusion on day 1. Results: Patients allocated to oxaliplatin plus LV5FU2 had significantly longer progression-free survival (median, 9.0 v 6.2 months; P 5 .0003) and better response rate (50.7% v 22.3%; P 5 .0001) when compared with the control arm. The improvement in overall survival did not reach significance (median, 16.2 v 14.7 months; P 5 .12). LV5FU2 plus oxaliplatin gave higher frequencies of National Cancer Institute common toxicity criteria grade 3/4 neutropenia (41.7% v 5.3% of patients), grade 3/4 diarrhea (11.9% v 5.3%), and grade 3 neurosensory toxicity (18.2% v 0%), but this did not result in impairment of quality of life (QoL). Survival without disease progression or deterioration in global health status was longer in patients allocated to oxaliplatin treatment (P 5 .004). Conclusion: The LV5FU2-oxaliplatin combination seems beneficial as first-line therapy in advanced colorectal cancer, demonstrating a prolonged progressionfree survival with acceptable tolerability and maintenance of QoL. J Clin Oncol 18:2938-2947. © 2000 by American Society of Clinical Oncology.